FactorX抗体;FactorX Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Factor X expression in HepG2 cell lysate.    

  
  

Factor X (FX), a vitamin K-dependent serine protease zymogen, plays a pivotal role in the coagulation cascade, serving as a convergence point for both intrinsic and extrinsic pathways. Its activated form, Factor Xa (FXa), is essential for thrombin generation and fibrin clot formation. FX antibodies, particularly those targeting FX or FXa, have emerged as critical tools in hematology research and clinical applications.

Monoclonal antibodies against FX/Xa are primarily used to study coagulation mechanisms, diagnose bleeding disorders (e.g., FX deficiency), or develop therapeutic strategies. For instance, andexanet alfa, a recombinant modified FXa decoy protein, acts as an antidote for FXa inhibitors (e.g., apixaban, rivaroxaban) by binding and neutralizing their anticoagulant effects. This innovation addresses the unmet need for reversing life-threatening bleeding in patients on direct oral anticoagulants.

FX antibodies also contribute to laboratory diagnostics, enabling precise quantification of FX activity in plasma. In autoimmune contexts, autoantibodies against FX (acquired FX inhibitors) are rare but associated with severe bleeding risks, necessitating immunosuppressive therapies. Recent research explores bispecific antibodies targeting FXa and other coagulation factors to enhance hemostatic control.

Overall, FX antibodies bridge translational research and clinical practice, offering insights into thrombosis, hemorrhage, and targeted anticoagulation therapies, while advancing personalized approaches in hemostasis management.